Biogen has deepened its partnership with Eisai Co., Ltd. to advance LEQEMBI, a monoclonal antibody targeting amyloid plaques in early Alzheimer’s disease. The collaboration leverages Eisai’s clinical expertise and Biogen’s manufacturing capabilities to accelerate global development. To date, joint trials have enrolled over 1,800 patients across North America, Europe and Asia Pacific, and interim data show a 27% slowing of cognitive decline over 18 months compared with placebo in high-dose cohorts.

The Chinese National Medical Products Administration has accepted the Biologics License Application for LEQEMBI’s subcutaneous formulation, a first in-home injection option for early Alzheimer’s. If approved, this would represent the inaugural anti-amyloid treatment available for at-home administration in China. Biogen projects peak annual sales in China of $1.2 billion by 2030, reflecting the country’s rapidly aging population and the absence of competing disease-modifying therapies.

Biogen recorded a 29.9% year-over-year increase in sales of Skyclarys, its treatment for Friedreich’s ataxia, reaching $132.9 million in the third quarter. LEQEMBI also contributed to revenue, with global sales of $210 million in the same period following its U.S. launch earlier this year. Overall, quarterly revenues rose 18% to $2.45 billion, fueled by higher pricing and expanded patient access programs across key markets.

Biogen’s share price has climbed 15.1% during 2025, reflecting investor confidence in the company’s late-stage pipeline and commercial execution. Equity analysts at UBS have set a target of $185 per share, citing robust adoption of LEQEMBI and the potential for additional label expansions. Trading volumes remain elevated, averaging 2.1 million shares daily, and market capitalization stands near $26.8 billion, underscoring the stock’s sustained liquidity and institutional interest.